Is Acute Hemodynamic Response a Predictor of Long-Term Outcome in Cardiac Resynchronization Therapy?
Reply
We thank Dr. Prinzen and colleagues for their interest in our study (1) . They comment that our results fit with physiological concepts regarding cardiac resynchronization therapy but are not supported by their findings that baseline rather than change in (the maximum rate of LV pressure rise LVdP/dt max ) predicted survival (2) .
We acknowledge that our study was limited by a small sample size and that our patients were a selected group meeting criteria for an inclusive research protocol. We used a 10% rise in LVdP/dt max to define acute response, which was supported by the receiveroperator analysis giving a cutoff of 11.1%, although this small increase did change the specificity to 86% from 64%. We found a moderate correlation between percentage rise in LVdP/dt max and extent of remodeling (r ϭ 0.6) but no relationship between baseline LVdP/dt max and remodeling. We used baseline atrial pacing to account for heart rate changes causing a rise in dP/dt max as described previously and our baseline dP/dt max was comparable to the reported study (2) .
We note the findings of Bogaard et al. (2) and would like to highlight several important differences between studies. Their patient population was different and predominantly ischemic: 56% versus 36% in our study. It is well described that cardiac resynchronization therapy response is worse in ischemic cardiomyopathy and 70% of their patients with events had ischemic cardiomyopathy (2). Importantly, we used LVdp/dt max to guide left ventricular lead placement, whereas Bogaard et al. measured dp/dt max after implantation and a guided approach may explain differences in remodeling and outcome. In keeping with our results, optimal left ventricular lead positioning produces marked variation in acute dp/dt max (3), better remodeling, and reduced events (heart failure hospitalizations/death) (4). It is also important to appreciate that remodeling may not always correlate with clinical outcome especially in ischemic cardiomyopathy patients.
Bogaard et al. (2) reported clinical outcome and remodeling or hospitalization for heart failure. Data were not consistently available or reported (nearly 50% of deaths were noncardiac or unknown) and they state that whether acute improvement in dP/dt max correlates to morbidity still needs to be determined (2) .
In summary, we are in agreement with Prinzen et al. that a prospective randomized controlled study will be needed to confirm a favorable effect of LVdP/dt max -guided therapy on prognosis and functional status after cardiac resynchronization therapy. 
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